PatentDe  


Dokumentenidentifikation EP1219301 06.09.2007
EP-Veröffentlichungsnummer 0001219301
Titel Impfstoffe, die hybride Polypeptide mit mindestens zwei verschiedene Allergenen enthalten
Anmelder Biomay Produktions- und Handels-Aktiengesellschaft, Wien, AT
Erfinder Linhart, Birgit, 3610 Weißenkirchen 95, AT;
Kraft, Dietrich Dr., 1170 Wien, AT;
Valenta, Rudolf Dr., 2604 Theresienfeld, AT
Vertreter derzeit kein Vertreter bestellt
DE-Aktenzeichen 60129528
Vertragsstaaten AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, TR
Sprache des Dokument EN
EP-Anmeldetag 20.12.2001
EP-Aktenzeichen 011302924
EP-Offenlegungsdatum 03.07.2002
EP date of grant 25.07.2007
Veröffentlichungstag im Patentblatt 06.09.2007
IPC-Hauptklasse A61K 39/36(2006.01)A, F, I, 20051017, B, H, EP
IPC-Nebenklasse A61P 37/00(2006.01)A, L, I, 20051017, B, H, EP   C07K 14/415(2006.01)A, L, I, 20051017, B, H, EP   C12N 15/62(2006.01)A, L, I, 20051017, B, H, EP   C12N 5/10(2006.01)A, L, I, 20051017, B, H, EP   C12N 1/21(2006.01)A, L, I, 20051017, B, H, EP   G01N 33/53(2006.01)A, L, I, 20051017, B, H, EP   C12N 15/29(2006.01)A, L, I, 20051017, B, H, EP   

Beschreibung[en]

Type I allergy is a genetically determined hypersensitivity disease affecting almost 500 million individuals worldwide. Immediate symptoms (allergic rhinoconjunctivitis, asthma, anaphylactic shock) as well as late symptoms (atopic dermatitis, certain forms of allergic asthma bronchiale) are based on the recognition of allergens by IgE antibodies. Immediate symptoms result from the allergen-induced crosslinking of effector cell-bound IgE and the subsequent release of biological mediators (e. g., histamine, leukotrienes) whereas late symptoms can be caused by IgE-mediated presentation of allergens to T cells and eosinophil activation.

The only curative therapy approach, allergen-specific immunotherapy, is based on the systemic administration of allergens to patients in order to induce allergen-specific "unresponsiveness" ( Noon, Lancet 1911, 1: 1572-1573 ; Bousquet et al. (1998) J Allergy Clin Immunol 102: 558-562 ; Durham and Till (1998) J. Allergy Clin. Immunol. 102, 157-164 ). Using conventional technologies it has not been possible to produce pure allergens for specific immunotherapy and hence, vaccination is performed with allergen extracts. These extracts consist of allergens and non-allergenic components which are difficult to standardize. Therefore patients cannot be treated according to their specific sensitization profile and anaphylactic side effects, due to the administration of allergenic material are frequently observed ( Mellerup et al. (2000). Clin. Exp. Allergy 30, 1423-1429 ). It is an objective of the present invention to provide an advantageous composition for the treatment or prevention of allergic disorders.

Surprisingly the inventors found that it is possible to generate hybrid allergens assembling the epitopes of immunologically distinct allergens for diagnosis and therapy of Type I allergy. The invention therefore relates to a hybrid polypeptide comprising at least two different allergenic proteins or fragments thereof wherein each fragment consists of at least eight consecutive amino acids of the respective allergenic protein, characterized in that the allergenic protein from which the hybrid polypeptide is derived consists of immunologically unrelated major timothy grass pollen allergens.

In one embodiment the hybrid polypeptide comprises at least one complete allergenic protein. It may also comprise two different complete allergenic proteins. It is not only possible to combine different groups of allergenic grass pollen but also to combine allergenic proteins derived from different sources. In a particular embodiment all sequences of the hybrid polypeptide derived from allergenic proteins represent complete allergenic proteins.

In another embodiment the hybrid polypeptide comprises at least one fragment of an allergenic protein wherein the fragment consists of at least eight consecutive amino acids of the respective allergenic protein. Preferably the fragment consists of at least 12, more preferably of at least 20 and most preferably of at least 30 consecutive amino acids of the respective allergenic proteins. In another embodiment all amino acid sequences derived from allergenic proteins are fragments of at least eight consecutive amino acids of the respective allergenic proteins from which they are derived. The preferred length of these fragments is at least 12, more preferably at least 20, most preferably at least 30 consecutive amino acids of the respective allergenic protein.

When fragments of allergenic proteins are employed it is possible to prepare a hybrid polypeptide comprising only fragments which have an allergenic activity which is lower compared with the respective allergenic proteins from which they are derived. This effect may be due to the destruction of epitopes by modified secondary or tertiary structure of the fragment compared with the full length protein. In the most preferred embodiment, the hybrid polypeptide has an allergic activity which is lower than the allergenic activity of each of the allergenic proteins from which the hybrid polypeptide is derived. Usually, the allergenic activity of the hybrid polypeptide is less than 50% of that of each of the allergenic proteins from which the hybrid polypeptide is derived. In a particular embodiment, the hybrid polypeptide has substantially no allergenic activity.

According to the invention the allergenic activity of a sample is determined by determining the IgE antibodies which are induced in a test animal upon application of the sample. The allergenic activity is preferably defined in suitable in vitro or in vivo tests. A preferred in vitro test is the basophil histamine release assay as described in Vrtala et al., J. Clin. Invest. 1997, 99, pp. 1673-1681 . Alternatively the allergenic activity is determined in a skin test as described in van Hage-Hamsten et al. J. Allergy Clin. Immunol. 1999, 104, pp. 969-977 or in Pauli et al. Clin. Exp. Allergy 2000, 30, pp. 1076-1084 .

In one embodiment the hybrid polypeptide comprises two portions which are derived from two different allergenic proteins. The hybrid polypeptide of the invention, however, may comprise three, four, five or even more portions each of which is derived from a different allergenic protein.

The hybrid polypeptide of the invention does not necessarily consist only of amino acid sequences derived from allergenic proteins. It is possible that artificial sequences (e.g. spacer sequences) are inserted between the units representing sequences from different allergenic proteins. It is also possible that the amino acid sequences of the naturally occurring allergenic proteins are modified, e.g. by genetic engineering to introduce mutations which reduce the allergenic activity of the fragment. It is also preferred that the hybrid polypeptide comprises a "tag" sequence which facilitates the purification of the hybrid polypeptide upon expression in a host cell. An example of a "tag" is the hexahistidine tag which allows purification by Ni2+ chelate chromatography. Other tags are known in the art.

The hybrid polypeptide of the invention may be prepared by several methods. In one embodiment the polypeptide is prepared by expressing a polynucleotide in a host cell. The host cell may be a procaryotic or a eucaryotic cell. If procaryotic cells are used the host is preferably E.coli. Examples of eucaryotic cells are yeast, insect cells or cell lines like CHO cells. After introducing a suitable polynucleotide encoding the polypeptide of the invention into a host cell the host cell is cultured under conditions such that the polypeptide is expressed in the cell. The polypeptide may be secreted by the cell or accumulate inside the cell. Known purification methods can be used to recover the hybrid polypeptide from the cell or from the culture medium.

The invention also encompasses the preparation of the hybrid polypeptide by chemical synthesis such as solid phase synthesis.

The invention further concerns a polynucleotide encoding a hybrid polypeptide according to the invention. Due to the degeneracy of the genetic code many different polynucleotide molecules may encode a single polypeptide. The polynucleotide of the invention preferably is an expression construct for obtaining the polypeptide after expression in host cells. The expression construct may further comprise components which are generally known in the art such as promoter sequences, genes encoding resistance factors against antibiotics, a replication origin etc.

The invention further relates to a cell transfected or transformed with a polynucleotide of the invention. The cell may be a eucaryotic cell or a procaryotic cell. Eucaryotic cells may be transfected by a method known per se such as calcium phosphate mediated transfection, electroporation, lipofection etc.

The invention further relates to a pharmaceutical composition containing a polypeptide, polynucleotide or a cell according to the invention. The pharmaceutical composition may further contain a pharmaceutically acceptable carrier or diluent such as a buffer or salt solution. Preferably the pharmaceutical composition of the invention is a vaccine composition. In a particular embodiment the pharmaceutical composition further contains an adjuvant such as Al(OH)3.

The invention also relates to a method for the preparation of a hybrid polypeptide of the invention. The method comprises providing a polynucleotide encoding a hybrid polypeptide, introducing said polynucleotide into a host cell, culturing the host cell thus obtained under conditions such that the hybrid polypeptide is expressed, and recovering the expression product from the cell. The polynucleotide may be prepared by methods known in the art, it is preferred that PCR technology is used to prepare the polynucleotide encoding the hybrid polypeptide.

The invention further concerns the use of a hybrid polypeptide, of a polynucleotide or of a cell of the invention for the preparation of a medicament for the treatment of an allergic disorder.

Such a medicament may be composed of the polynucleotide encoding a hybride vaccine which can be used directly for DNA-based vaccination against Type I allergy. The recombinant or synthetic hybrid polypeptide may be used to prepare formulations for the oral, sublingual or parenteral treatment of Type I allergic disorders as they are now routinely used for immunotherapy. Examples are formulations for sublingual immunotherapy or adjuvant bound hybrid polypeptides for injection immunotherapy. Possible applications comprise also cell based forms of immunotherapy which may be based on e.g., dendritic cells or other antigen presenting cells. Those cells are transformed and express the antigen in vivo. Preferably autologous cells transformed with suitable vectors are used.

One mode of applications may be the subcutaneous injection of adjuvant-bound hybrid polypeptides. Another possibility is the oral or nasal administration of the hybrid polypeptide in order to induce immunological tolerance or anergy against the components of the hybrid polypeptides. All these possible formulations can be prepared according to rules (dosage, adjuvants, schemes of administration) which are known to the person skilled in the art.

The invention also relates to the use of a hybrid polypeptide, of a polynucleotide, or of a cell of the invention for the preparation of a medicament for prophylactic vaccination or tolerance induction. Prophylactic administration of hybride polypeptides means the administration of the polypeptide to individuals, preferentially children, who do not yet suffer from Type I allergy in order to induce a state of immunological tolerance, anergy or non-responsiveness, or a protective immunity against the components of the hybrid vaccine. This may be achieved by the various protocols outlined for treatment of an established allergic disorder. The prophylactic treatment may be performed with hybrid polypeptides consisting of hybride polypeptides or the polynucleotides coding for the hybrid polypeptides as outlined before.

In a further embodiment the invention relates to the use of a hybrid polypeptide of the invention for the detection of antibodies against an allergenic protein in a sample. The antibody may be an IgM, IgE, IgG or IgA antibody. The concentration of the antibody may be determined from a sample which has been obtained from a body fluid. The sample may be derived from animals or humans. Such tests may use a solid phase-immobilized hybrid polypeptide or the hybrid polypeptide in the fluid phase. Examples for such tests may be ELISA tests. Westernblotting tests or any other test where the hybrid polypeptide is immobilized to bind specific antibodies out from the test sample. Alternatively the hybrid polypeptide is added directly to the antibody-containing fluid in order to adsorb specific antibodies as e.g., is done for competitive immunological assays.

The polypeptide of the invention may also be used for cellular tests such as a T-cell proliferation test, mediator release test etc. The hybridpolypeptide may be exposed to various types of cells in order to elicit measurable responses. Such responses may comprise the release of histamine or other mediators (e.g., leukotriens, serotonine, ECP) in the case of allergic effector cells (e.g., basophils mast cells, eosinophils). In another type of assay the proliferation or death (e.g., apoptosis) of cells may be measured e.g., by the uptake of 3H Thymidine or any other suitable assay. Such cells may be T cells. Furthermore, hybrid polypeptides may be used to induce the release of cytokines or other immunologically relevant substances (e.g., from T cells) that can be measured. Furthermore, they may be used for antigen presentation assays. The hybrid polypeptide of the invention may also be used for diagnostic screening purposes. Hybrid polypeptides may be also used for in vivo provocation testing. Such tests may comprise skin testing (e.g., skin prick or intradermal testing), nasal provocation testing, all forms of food challenge testing or bronchial provocation testing.

Since hybrid polypeptides can contain epitopes of unrelated allergens they may be used for diagnostic screening tests (in vitro, in vivo as outlined above) in order to detect sensitization or unresponsiveness against one of the components of the hybrid polypeptide. This may allow to provide the physician with a diagnostic test which is suited to screen for sensitized patients in a fast way. Currently such tests (e.g., Phadiatop, Pharmacia, Uppsala, Sweden) consist of a mixture of non-covalently bound allergens which are coupled to one carrier. Therefore, the coupling rate of the individual components is difficult to control whereas a hybrid polypeptide would represent a preferential formulation for the preparation of such a screening test.

More than 40% of allergic patients are sensitized to grass pollens from different species. Grasses are also important allergen sources because of their worldwide distribution and heavy pollen production. They contain a variety of different allergenic components which occur as crossreactive allergens in different monocots. The inventors demonstrated that it is possible to generate by recombinant DNA technology hybrid allergens which consist of immunologically unrelated allergens and their epitopes.

In a first step frequent co-sensitizations were determined using purified recombinant timothy grass pollen allergens to select the most frequently recognized allergen combinations for the hybrid allergen approach. According to the pilot experiments hybrids consisting of immunologically unrelated major timothy grass pollen allergens were engineered. They comprised hybrids of the major timothy grass pollen allergens Phl p 5/Phl p 1, Phl p 2/Phl p 6 and a combination of all four molecules. As demonstrated for Phl p 2/Phl p 6 we found no evidence that a certain order of engineering the individual components would affect the presentation of epitopes. Both, the rPhl p 2/Phl p 6 hybrid and the rPhl p 6/Phl p 2 hybrid preserved the relevant B and T cell epitopes of the components. The giant consisting of all 4 allergens also contained the relevant epitopes of the single components.

The hybrid allergen approach will open new avenues for diagnosis and treatment of Type I allergy. Hybrids consisting of the most frequently recognized allergens with preserved epitopes represent candidate molecules for in vitro as well as in vivo allergy screening tests. The giant described in the present application will likely identify more than 95% of timothy grass pollen allergic patients when used for diagnosis, because it resembles most of the relevant IgE epitopes present in natural timothy grass pollen extract. Molecules such as the giant can be produced also for other allergen systems (e. g., mite allergy). The advantage of using hybrid allergens for diagnosis is that they can be produced in a well controlled manner. In contrast to natural allergen extracts, which consist of a difficult to standardize mixture of allergens and non-allergenic materials, hybrid allergens will contain the relevant epitopes in a well defined ratio.

Recombinant hybrid allergens can also be used for immunotherapy. They can either be composed of the biologically active components or of hypoallergenic allergen units. Hybrid allergens covering frequent co-sensitization patterns may then be used for the treatment of allergies to complex allergen sources, e.g., grass pollen allergy because they resemble the relevant epitopes of the complete extract. Since the hybrid allergens consist of defined components it will be possible to produce well defined formulations for vaccination treatment. Hybrid allergens produced out of hypoallergenic variants will be tolerated in high doses and thus can be used like vaccines regularly used for prevention of viral infections. In this respect it may be considered to use hybrid allergens containing the epitopes of the most relevant allergens for prophylactic vaccination or tolerance induction even in not yet sensitized individuals.

The fact that the fusion of different antigenic components in form of a hybrid molecule increased the immunogenicity of the individual components has several implications for allergen-specific immunotherapy and for vaccination in general. Allergens or antigens against which immune responses are desired and which per se exhibit low immunogenicity can be fused to hybrids to increase their immunogenicity without using other carrier proteins or adjuvants. This principle will allow to induce high levels of protective antibody responses against allergens, allergen fragments, allergen epitopes or mimicks thereof. Using this principle it is also possible to increase the immune response towards antigens/epitopes derived from infectious agents, tumors or other components against which it is difficult to induce immune responses.

Description of the tables and figures:

  • Table 1 shows the percentage inhibition of IgE binding to recombinant Phl p 2 and Phl p 6 achieved after preadsorption of sera from 20 patients with the hybrid allergens (rPhl p 2/rPhl p 6, rPhl p 6/rPhl p 2) or the recombinant allergens (rPhl p 2, rPhl p 6).
  • Table 2 shows the percentage inhibition of IgE binding to recombinant Phl p 1, Phl p 5, and Bet v 1 achieved after preadsorption of sera from 20 patients with the hybrid allergen rPhl p 5/rPhl p 1 or the recombinant allergens (rPhl p 1, rPhl p 5, and rBet v 1).
  • Table 3. Mouse antisera raised against hybrid molecules inhibit the binding of grass pollen allergic patients IgE to the individual allergens. ELISA plate-bound allergens (A: rPhl p 2 and rPhl p 6; B: rPhl p 1 and rPhl p 5) were preincubated with mouse antisera (mouse anti-rP2-P6, anti-rP6-P2, anti-rPhl p 2, anti-rPhl p 6, anti-rP5-P1, anti-rPhl p 1, anti-rPhl p 5. The percentages inhibition of IgE binding obtained for 4 grass pollen allergic patients are displayed.
  • Figure 1 shows the frequency of co-sensitization to timothy grass pollen allergens rPhl p 1, rPhl p 2, rPhl p 5, and rPhl p 6 as determined in a population of 110 grass pollen allergic patients.
  • Figure 2 outlines the construction of hybrid vaccines. The fusion of the two genes (e.g. Phl p 5, Phl p 1) is mediated by a two-step PCR reaction, creating overlapping ends in the first PCR reaction followed by the amplification of both sequences in a second PCR step.
  • Figure 3 shows the result of example 3. Purified timothy grass pollen allergens (rPhl p 1, rPhl p 2, rPhl p 5, and rPhl p 6) and hybrids of them (rPhl p 5/rPhl p 1, rPhl p 2/rPhl p 6, and rPhl p 6/rPhl p 2) were loaded on a SDS polyacrylamide gel and stained with Coomassie brilliant blue. Molecular weights are displayed at the left margin.
  • In figure 4 (A) a purified recombinant hybrid consisting of Phl p 6/Phl p 2/Phl p 5/Phl p 1 was dotted on nitrocellulose filters. In row (B) rPhl p 2 (lane 1,3,4,and 5) and rPhl p 5 (lane 2) was immobilized. Filters were incubated with rabbit antisera against rPhl p 1 (lane 1), rPhl p 2 (lane 2), rPhl p 5 (lane 3), and rPhl p 6 (lane 4). The filter in lane 5 was exposed to a mouse monoclonal anti-His-tag antibody.
  • Figures 5 to 7 show that recombinant hybrid molecules induce stronger lgG1 antibody responses in mice than the individual components or mixtures thereof.
  • Figure 5. ELISA plate-bound purified recombinant allergens (A: rPhl p 2: B: rPhl p 6; C: rPhl p 1; D: rPhl p 5) were incubated with sera from mice (8 mice per group) which had been immunized with the hybrid molecules (rP2-P6, rP6-P2, rP5-P1), the individual recombinant allergens (rPhl p 1, rPhl p 2, rPhl p 5, rPhl p 6), or with timothy grass pollen extract as indicated on the x-axis. Mean lgG1, levels of sera collected 4 and 8 weeks after immunization correspond to the OD values displayed on the y-axis.
  • Figure 6. ELISA plate-bound purified recombinant allergens (rPhl p 1, rPhl p 2, rPhl p 5, rPhl p 6) were incubated with sera from mice (8 mice per group) which had been immunized with (A) the giant molecule or the individual recombinant allergens rPhl p 1, rPhl p 2, rPhl p 5, rPhl p 6, and with (B) the giant molecule or an equimolar mixture of rPhl p 1, rPhl p 2, rPhl p 5,and rPhl p 6 as indicated on the x-axis. Mean lgG1, levels of sera collected 4 and 8 weeks after immunization correspond to the OD values displayed on the y-axis.
  • Figure 7. The ELISA plate-bound giant (A), and timothy grass pollen extract (B) were incubated with sera from mice (8 mice per group) which had been immunized with the giant or timothy grass pollen extract as indicated on the x-axis. Mean IgG1 levels of sera collected 4 and 8 weeks after immunization correspond to the OD values displayed on the y-axis.

The following examples further illustrate the invention:

Example 1: Determination of frequent co-sensitization patterns

Grasspollen contain a variety of immunologically distinct and related allergens. These components are recognized at different frequencies and intensities. Recombinant timothy grass pollen allergens, rPhl p 1, rPhl p 2, rPhl p 5, and rPhl p 6, were previously identified as the most important components which resemble most of the IgE epitopes of natural grass pollen extracts ( Niederberger et al. (1998) IgE antibodies to recombinant pollen allergens (Phl p 1, Phl p 2, Phl p 5, and Bet v 2) account for a high percentage of grass pollen-specific IgE. J Allergy Clin Immunol 101: 258-264 ). The results of the evaluation of co-sensitizations in 110 grass pollen allergic patients to combinations of the recombinant timothy grass pollen allergens are displayed in Figure 1. ELISA testing with purified recombinant allergens showed that 60% percent of the patients were co-sensitized to rPhl p 1 and rPhl p 5, 30% contained IgE antibodies to rPhl p 2 and rPhl p 6 and 30% reacted simultaneously to all four recombinant allergens (Figure 1). Previous competition studies had indicated that a mixture of the above four allergens contained the majority of IgE epitopes present in 8 different monocot pollens (grasses, corn) ( Laffer et al. (1996) Comparison of recombinant timothy grass pollen allergens with natural extract for diagnosis of grass pollen allergy in different populations. J Allergy Clin Immunol; 98: 652-658 ).

Patients sera, antisera and recombinant allergens:

Sera of 110 allergic patients were characterized by a positive timothy grass pollen RAST (radioallergosorbent test) result and by determination of IgE antibodies to timothy grass pollen extract by Western blotting as described ( Niederberger et al. (1998) J Allergy Clin Immunol 101: 258-264 ). The recombinant timothy grass pollen allergens rPhl p 1, rPhl p 2, rPhl p 5, and rPhl p 6 were purified as described previously ( Vrtala et al. (1995) J.Allergy Clin. Immunol 97: 781-787 ; Vrtala et al. (1999) J. Immunol. 163:5489-5496 ). The rabbit anti-rPhl p 1, anti-rPhl p 2, anti-rPhl p 5, and anti-rPhl p 6 antisera were raised against purified rPhl p 1, rPhl p 2, rPhl p 5, and rPhl p 6 using CFA (Charles River, Kissleg, Germany).

Example 2: Construction of recombinant hybrid allergens

The protocol for the construction of recombinant hybrid allergens is displayed in Figure 2. As exemplified for a hybrid consisting of rPhl p 5 linked to rPhl p 1, cDNAs coding for the components are amplified with suitable primer pairs (Figure 2: Phl p 5: w, x; Phl p 1: y, z) in order to create overlapping ends. In a subsequent second PCR reaction, a cDNA comprising both cDNAs is created with primers specific for the 5' end of the first cDNA (Phl p 5: w) and the 3' end of the second cDNA (Phl p 1: z) using both PCR products of the first reactions as templates. Using this technology we produced recombinant hybrids consisting of a combination of Phl p 5/Phl p 1, rPhl p 2/rPhl p 6, rPhl p 6/rPhl p 2 and of all four allergens (N-terminus-rPhl p 6-rPhl p 2-rPhl p 5-rPhl p 1-C-terminus), the latter referred to as the "giant".

Construction of expression plasmids for rPhl p 5/rPhl p 1-, rPhl p 2/rPhl p 6-, rPhl p 6/rPhl p 2-, and rPhl p 6/rPhl p 2/rPhl p 5/rPhl p 1 hybrid proteins:

The cDNAs of Phl p 5 and Phl p 1 were obtained by polymerase chain reaction using the primers 5'GGA ATT CAT ATG GCC GAT CTC GGT TAC 3' (SEQ ID NO: 1)and 5' CGG GGT ACC GAC TTT GTA GCC ACC AGT 3' (SEQ ID NO: 2) for Phl p 5 and 5' CGG GGT ACC ATG ATC CCC AAG GTT CCC 3' (SEQ ID NO: 3) and 5' CGG GAT CCT CAG TGG TGG TGG TGG TGG TGC TTG GAC TCG TAG CTG GT 3' (SEQ ID NO: 4) for Phl p 1. The signal peptide of Phl p 5 was replaced by a Ndel restriction site, containing the ATG start codon at the 5'end of the coding region. A Kpnl restriction site was introduced at the 3 end of Phl p 5 replacing the stop-codon. The Phl p 1 sequence, lacking the signal peptide, started with a Kpnl restriction site at the 5'end. At the 3'end a nucleotide strect coding for a Hexahistidine-tag was introduced, followed by a stop codon and a BamHI restriction site. The PCR products were inserted as Ndel/Kpnl/BamHl fragment into a pET17b expression vector.

The Phl p 2/Phl p 6 and Phl p 6/Phl p 2 sequences were constructed using PCR based 'gene soeing' (17). In a first PCR reaction the cDNAs of Phl p 2 and Phl p 6 were amplified using the primers 5' GGA ATT CAT ATG GTG CCG AAG GTG ACG 3' (SEQ ID NO: 5), and 5' CGT GGC CTT CCC CAT AAG CTT CTC TTC TGG CGC GTA GGT 3' (SEQ ID NO: 6) for Phl p 2 and 5' AAG CTT ATG GGG AAG GCC ACG ACC 3' (SEQ ID NO: 7) and 5' C GGG ATC CTA GTG GTG GTG GTG GTG GTG CGC GCC GGG CTT GAC AGC 3' (SEQ ID NO: 8) for Phl p 6 to create overlapping ends. In a subsequent PCR reaction the two agarose gel purified PCR products (using QIAGEN gel purification kit) were used as templates and amplified using the primers 5' GGA ATT CAT ATG GTG CCG AAG GTG ACG 3' (SEQ ID NO: 9) and 5' C GGG ATC CTA GTG GTG GTG GTG GTG GTG CGC GCC GGG CTT GAC AGC 3' (SEQ ID NO: 10). The signal peptide of Phl p 2 was replaced by a Ndel restriction site at the 5'end, the stop codon at the 3'end was removed. In the Phl p 6 sequence, also lacking the signal peptide, a Hexahistidine tag was introduced followed by a stop codon and a BamHl restriction site. The resulting Phl p 2/Phl p 6 construct was inserted as a Ndel/BamHl fragment into the pET17b expression vector.

The Phl p 6/Phl p 2 sequence was constructed using the same method with the PCR primers 5' GGA ATT CAT ATG GGG AAG GCC ACG ACC GAG 3' (SEQ ID NO: 11) and 5' CAC CTT CGG CAC CAT AAG CTT CGC GCC GGG CTT GAC AGC 3' (SEQ ID NO: 12) for PhI p 6 and 5' AAG CTT ATG GTG CCG AAG GTG ACG 3' (SEQ ID NO: 13) and 5' C GGG ATC CTA GTG GTG GTG GTG GTG GTG CTC TTC TGG CGC GTA GGT 3' (SEQ ID NO: 14) for Phl p 2 in the first PCR reaction and the primers 5' GGA ATT CAT ATG GGG AAG GCC ACG ACC GAG 3' (SEQ ID NO: 15) and 5' C GGG ATC CTA GTG GTG GTG GTG GTG GTG CTC TTC TGG CGC GTA GGT 3' (SEQ ID NO: 16) for the second PCR reaction. The resulting Phl p 6/Phl p 2 construct was inserted in the pET17b vector as a Ndel/BamHl fragment.

For the construction of the Phl p 6/Phl p 2/Phl p 5/Phl p 1 hybrid ("giant") the Phl p 6/Phl p 2 construct was taken as a template in a PCR reaction using the primers 5' GGA ATT CAT ATG GGG AAG GCC ACG ACC GAG 3' (SEQ ID NO: 17) and 5' GGG ATT TCC ATA TGC TCT TCT GGC GCG TAG G 3' (SEQ ID NO: 18) replacing the 3'Hexahistidine tag and the stop codon by an Ndel restriction site. The sequence was cloned into the pET17b vector, containing the Phl p 5/Phl p 1 construct as a Ndel fragment. The right orientation of the insert was examined by restriction digest.

Example 3: Expression and purification of hybrid allergens

Recombinant hybrid allergens with a C-terminal hexahistidine tag were expressed in E. coli BL21 (DE3) and purified by Nickel affinity chromatography. The rPhl p 2/rPhl p 6 and rPhl p 6/rPhl p 2 hybrid were purified from the soluble cytoplasmic fraction of E. coli extracts whereas the rPhl p 5/rPhl p 1 hybrid and the "giant" were solubilized from the insoluble inclusion body fraction of E. coli in urea. Figure 3 shows a Coomassie-stained SDS-PAGE containing three of the hybrids and the single recombinant allergens. The molecular mass determined by SDS-PAGE corresponded to the molecular weight calculated for the hybrids on the basis of their deduced amino acid sequence (rPh l p 5/rPhl p 1:60kDa ; rPhl p 2/rPhl p 6 and rPhl p 6/rPhl p 2:22kDa ; "giant": 82kDa; data not shown).

Experimental protocol:

All constructs were expressed in E.coli BL21 (DE3). Cells were grown in LB-medium containing 100mg/l ampicillin to an OD600 of 0.8. The expression of the recombinant proteins was induced by adding isopropyl-&bgr;-thiogalactopyranoside (IPTG) to a final concentration of 0.5mM. After 4 hours at 37°C cells were harvested by centrifugation.

rPhl p 2/rPhl p 6 and rPhl p 6/rPhl p 2 were expressed as soluble proteins. Cells were resuspended in lysis buffer (50mM NaH2PO4, 300mM NaCI, 10mM imidazole, pH 8.0) and lysed with an ultraturrax (Polytron, Kinematica AG, Switzerland). The lysate was centrifuged at 10,000xg for 30min at 4°c to pellet the cellular debris. The supernatant was loaded on a Ni-NTA column (QIAGEN), the proteins were eluted with 250mM imidazole and dialyzed against water.

rPhl p 5/rPhl p 1 and rPhl p 6/rPhl p 2/rPhl p 5/rPhl p 1 were expressed in the inclusion body fraction. Cells were resuspended in 10mM Tris, 0.1% Triton, pH 7.4 and lysed by adding lysozyme to 1mg/ml. After centrifugation at 14 000xg for 20min at 4°C the pellet was washed 4x with 5mM Tris pH 8.0, 0.05M NaCl, 0.25% Desoxicholate, 0.25mM p-Mercaptoethanol and once with 10mM Tris, pH 8.0, 3% isopropanole. Inclusion bodies were solubilized with 8M urea, 100mM NaH2PO4, 10mM Tris, pH 8.0. After centrifugation at 14 000xg for 20min the supernatant was loaded on a Ni-NTA column (Qiagen). The proteins were renatured on the column using a linear 6M-1M urea gradient in 500mM NaCI, 20% glycerol, 20mM Tris, pH 7.4) over a period of 1.5h (18). Proteins were eluted by addition of 250mM imidazole and dialyzed against PBS pH 7.4.

Example 4: Hybrid allergens contain the relevant epitopes of their components

Recombinant hybrid allergens contained the complete primary amino acid sequences of their components and thus the complete repertoire of T cell epitopes of the single allergens. The presence of B cell epitopes was investigated with antibodies of predefined specificity for the individual components and by immunological competition experiments. Figure 4 shows that the "giant" is recognized by antisera raised against rPh I p 1, rPhl p 2, rPhl p 5 and rPhl p 6, respectively (Figure 4, row A: 1-4). The correct expression of the C-terminal hexahistidine tag was demonstrated by the reactivity of a mouse monoclonal anti-Histag antibody which specifically recognized the "Giant (Figure 4: row A, 5) but not rPhl p 2 containing no hexahistidine tag (Figure 4: row B, 5). Recombinant Phl p 2 (row B: 1, 3, 4) and rPhl p 5 (row B: 2) (negative controls) did not react with the antisera (Figure 4: row B).

Next we investigated whether the hybrid allergens can be used to block the binding of grass pollen allergic patients (n=20) IgE antibodies to the individual components (Tables 1, 2). Table 1 shows that the rPhl p 2/rPhl p 6 as well as the rPhl p 6/rPhl p 2 hybrid inhibited IgE binding to both of the components (rPhl p 2, rPhl p 6) in a comparable manner as the single recombinant allergens (approximately 80% inhibition of IgE binding). Likewise, we found that the rPhl p 5/rPhl p 1 hybrid inhibited IgE binding of the 20 patients to both, rPhl p 1 and rPhl p 5, as efficient as the single components (average inhibition 85%) (Table 2). No inhibition was observed when sera were preadsorbed with the rPhl p 5/rPhl p 1 hybrid and reacted with an unrelated allergen (major birch pollen allergen, Bet v 1) whereas rBet v 1 caused almost complete autoinhibition (83% inhibition) (Table 2).

Experimental protocol: ELISA competition experiments:

Sera from 20 patients were diluted 1:10 in Tris-buffered saline (TBS) for the inhibition with rPhl p 5/rPhl p 1 and 1:5 for inhibition with rPhl p 2/rPhl p 6 and rPhl p 6/rPhl p 2. The sera were preadsorbed overnight at 4°C either recombinant Phl p 1, Phl p 5, Phl p 5/Phl p 1, Phl p 2, Phl p 6, Phl p 2/Phl p 6, Phl p 6/Phl p 2, Bet v 1, or BSA (10µg/ml). ELISA plates were coated with recombinant Phl p 1, Phl p 2, Phl p 5, Phl p 6, and Bet v 1 (5µg/ml) at 4°C overnight. The ELISA was performed as described ( Niederberger et al. (1998) J Allergy Clin Immunol 101: 258-264 ).

Dot blots:

Aliquots of approximately 1 µg of purified, recombinant Phl p 6/Phl p 2/Phl p 5/Phl p 1, and rPhl p 5 and rPhl p 2 as negative controls, were dotted on nitrocellulose membranes. Filters were blocked with TBS, 1% BSA, 0.05% Tween-20 for 1 hour and incubated with rabbit anti-Phl p 1, anti-Phi p 5 (diluted 1:5000), anti-Phl p 2 (diluted 1:500),anti-Phl p 6 (diluted 1:2000) sera, and a mouse monoclonal anti-Hexahistidin Ab (Dianova, Germany) diluted 1:1000 in TBS, 1%BSA, 0.05% Tween-20. Filters were washed 3x with TBS. 0.05% Tween-20, incubated with a secondary alkaline phosphatase-coupled goat anti-rabbit IgG antibody (Jackson) and for the His-tag detection with a alkaline phosphatase-coupled anti-mouse IgG antibody (PharMingen) diluted 1:1000 in TBS, 1%BSA, 0.05% Tween-20 for 1 hour, and washed 3x with TBS, 0.05% Tween-20. Colour reaction was started by adding NBT/BCIP (300µg/ml) and stopped by the addition of water.

Example 5: Hybridmolecules induce stronger immune responses in mice than the individual components or mixtures thereof.

To evaluate wether immunization with the hybrid allergens induces IgG antibodies that recognize the individual allergen components, groups of 8 mice each were immunized with the hybrids, the individual allergens or timothy grass pollen extract. Figure 5 demonstrates that the average IgG1 responses induced by the hybrid molecules to each of the individual allergens (rPhl p 1, rPhl p 2, rPhl p 5, or rPhl p 6) were higher than those obtained by immunization with the single allergen components. High IgG1 antibody levels induced by the hybrids were already detectable 4 weeks after the first immunization and had increased further after 4 more weeks. Perhaps most interesting was the finding that the hybrid molecules induced higher IgG1 levels to the individual allergen components than timothy grass pollen extract (Figure 5). The latter was particularly evident for Phl p 2, Phl p 6 and Phl p 1 which were poorly recognized by extract-induced antibodies, whereas the hybrid molecules induced vigorous anti-Phl p 1-, anti-Phl p 2- and anti-Phl p 6 antibody responses (Figure 5).

Likewise we found that immunization with the giant molecule induced stronger antibody responses to each of the components (Phl p 1, Phl p 2, Phl p 5, Phl p 6) than immunization with the individual antigens (Figure 6A) or an equimolar mixture of the antigens (Figure 6B). Immunization with the giant yielded also better immune responses than immunization with timothy grass pollen extract. IgG antibodies induced with timothy grass pollen extract exhibited lower reactivity to the giant and to the extract than those induced with the giant (Figure 7A, B).

Immunization of mice and measurement of specific antibody levels

Groups of 8 female BALB/c mice (age: 8 weeks) (Charles River, Germany) were immunized subcutaneously with rPhl p 1, rPhl p 2, rPhl p 5, rPhl p 6, rP2-P6, rP6-P2, rP5-P1, the giant molecule, timothy grass pollen extract, or an equimolar mixture of rPhl p 1. rPhl p 2, rPhl p 5, and rPhl p 6 adsorbed to Al(OH)3 (Alu-Gel-S, Serva, Ingelheim, Germany). Animals were maintained in the animal care unit of the Institute of Pathophysiology, University of Vienna, according to the local guidelines for animal care. Mice were immunized and bled from the tail veins in four-week intervals and sera were stored at -20°C until analysis.

IgG1 responses against rPhl p 1, rPhl p 2, rPhl p 5, rPhl p 6, rP2-P6, rP6-P2, rP5-P1, the giant molecule, an equimolar mixture of rPhl p 1, rPhl p 2, rPhl p 5, and rPhl p 6, and timothy grass pollen extract were measured by ELISA. Allergens (recombinant allergens: 5µg/ml; extract: 50µg/ml) were coated to Nunc Maxisorp plates (Roskilde, Denmark) and incubated with 1:1000 diluted mouse-sera. Bound antibodies were detected with a 1:1000 diluted monoclonal rat anti-mouse IgG1 (Pharmingen, San Diego, CA, USA) and a 1:2000 diluted HRP-labeled sheep anti-rat antiserum (Amersham, Buckinghamshire, UK).

Example 6: Hybrid molecules induce protective antibody responses that block the binding of allergic patients' IgE to grass pollen allergens

Next we examined whether mouse antibodies induced with the hybrid molecules can block the binding of grass pollen allergic patients IgE antibodies to purified grass pollen allergens (Table 3). ELISA competition experiments performed with sera from 4 representative grass pollen allergic patients showed that antibodies induced by the hybrid molecules strongly inhibited IgE binding to the purified allergens: IgG antibodies induced with the rP2-P6 and the rP6-P2 hybrid molecule caused a 48%-54% inhibition of IgE binding to Phl p 2 and a 54%-67% inhibition of IgE binding to Phl p 6 (Table 3A). By contrast, the inhibition of IgE reactivity yielded by preincubation with antibodies induced with rPhl p 2 and rPhl p 6 alone was very low (0-15%) (Table 3A). Anti-P5-P1 antibodies caused a more than double inhibition of IgE binding to Phl p 5 (59.5% average inhibition) than antibodies raised against Phl p 5 alone (28%) (Table 3B). The inhibition of IgE binding to Phl p 1 yielded with the antibodies raised against the rP5-P1 hybrid (18.5% average inhibition) and Phl p 1 alone (29.5% average inhibition) were lower (Table 3B).

Similar results were obtained with the giant molecule which induced IgG antibodies that efficiently blocked the binding of grass pollen allergic patients IgE to Phl p 1, Phl p 2, Phl p 5, Phl p 6 and timothy grass pollen extract (data not shown).

ELISA for assessment of blocking antibody activity

The ability of the mouse anti-rP2-P6, anti-rP6-P2, and anti-rP5-P1 antibodies to inhibit the binding of grass pollen allergic patients' IgE Abs to rPhl p 1, rPhl p 2, rPhl p 5, or rPhl p 6 was examined by ELISA competition experiments. Recombinant Phl p 1, Phl p 2, Phl p 5, and Phl p 6 (1µg/ml) were coated to ELISA plates (Nunc) over night at 4°C, plates were washed twice with TBST (Tris-buffered saline, 0.05% Tween), saturated with 200µl TBST/1%BSA, and preincubated with mouse anti-rP2-P6, anti-rP6-P2, and anti-rP5-P1 antisera or, for control purposes, with the corresponding preimmune sera each diluted 1:50 in TBST/0.5%BSA over night at 4°C. After washing 5 times with TBST, plates were incubated with human sera from grass pollen allergic patients diluted 1:5 in TBST/0.5%BSA over night at 4°C. After washing 5 times with TBST, bound human IgE was detected with an AP-labeled mouse anti-human IgE Ab (Pharmingen) diluted 1:1000 in TBST/0.5%BSA (1 hour at 37°C, 1 hour at 4°C). After washing 5 times with TBST, the colour reaction was started by adding 100 µl ELISA substrate (Sigma Diagnostics, Inc., St. Louis, USA) The percentage of reduction of human IgE binding after preincubation with mouse antisera was determined according to the formula: %inhibition of IgE binding = 100-ODl/ODP x 100. ODl and ODP represent the extinctions after preincubation with the immune serum and the preimmune serum, respectively. Table 1. Patient rPhl p 2 rPhl p 2/rPhl p 6 rPhl p 6/rPhl p 2 rPhl p 6 rPhl p 2/rPhl p 6 rPhl p 6/ rPhl p 2 1 69 72 78 72 72 73 2 72 78 81 81 80 81 3 97 95 98 93 91 97 4 93 93 94 80 80 80 5 79 79 78 69 76 75 6 44 44 45 80 82 82 7 97 97 97 87 97 96 8 92 93 92 84 93 93 9 84 85 85 64 68 68 10 53 56 56 45 53 52 11 83 84 82 78 93 91 12 67 64 65 70 72 71 13 90 89 89 86 91 91 14 94 94 93 85 89 89 15 81 81 81 86 89 95 16 97 96 97 95 96 96 17 97 97 94 95 97 97 18 90 90 91 43 53 52 19 76 75 76 68 83 82 20 97 97 97 73 89 89 mean 83 83 84 77 82 83 rPhl p 2 coated rPhl p 6 coated
Table 2. Patient rPhl p 1 rPhl p 5/ rPhl p 1 rPhl p 5 rPhl p 5/ rPhl p 1 rBet v 1 rPhl p 5/ rPhl p 1 1 77 81 85 83 74 0 2 90 89 94 92 96 18 3 96 92 96 92 67 0 4 92 92 95 90 - - 5 82 84 87 87 - - 6 92 93 93 93 75 9 7 88 90 90 91 97 0 8 90 91 93 92 88 2 9 50 52 57 57 59 4 10 89 89 93 90 58 5 11 88 95 89 94 - - 12 95 95 95 96 97 0 13 94 96 94 95 97 0 14 95 96 95 95 98 0 15 78 78 81 79 92 0 16 94 95 95 94 94 0 17 46 58 66 65 - - 18 77 78 86 85 63 42 19 91 91 94 93 - - 20 95 93 97 95 96 32 mean 85 86 89 88 83 7 rPhl p 1 coated rPhl p 5 coated rBet v 1 coated
Table 3 A % Inhibition of IgE Binding to rPhl p 2 rPhl p 6 rPhl p 2 rPhl p 6 rPhl p 2 rPhl p 6 with mouse anti-rP2-P6 mouse anti-rP6-P2 mouse anti-rPhl p 2 mouse anti-rPhl p 6 patient 1 56 62 48 63 0 5 2 38 63 38 65 0 29 3 56 39 53 65 0 18 4 65 52 54 75 0 9 mean 54 54 48 67 0 15 B rPhl p 1 rPhl p 5 rPhl p 1 rPhl p 5 with mouse anti-rP5-P1 mouse anti-rPhl p 1 mouse anti-rPhl p 5 patient 1 16 59 33 23 2 19 67 39 15 3 14 69 17 40 4 25 43 29 33 mean 19 60 30 28

SEQUENCE LISTING

  • <110> SHAN-Beteiligungsgesellschaft m.b.H.
  • <120> Allergy vaccines containing hybrid polypeptides
  • <130> Allergy vaccines containing hybrid polypeptides
  • <140>

    <141>
  • <150> EP-A 00.128660.8

    <151> 2000-12-28
  • <160> 18
  • <170> PADAT Sequenzmodul, Version 1.0
  • <210> 1

    <211> 27

    <212> DNA

    <213> artificial sequence
  • <220>

    <223> primer
  • <400> 1

    ggaattcata tggccgatct cggttac    27
  • <210> 2

    <211> 27

    <212> DNA

    <213> artificial sequence
  • <220>

    <223> primer
  • <400> 2

    cggggtaccg actttgtagc caccagt    27
  • <210> 3

    <211> 27

    <212> DNA

    <213> artificial sequence
  • <220>

    <223> primer
  • <400> 3

    cggggtacca tgatccccaa ggttccc    27
  • <210> 4

    <211> 47

    <212> DNA

    <213> artificial sequence
  • <220>

    <223> primer
  • <400> 4

    cgggatcctc agtggtggtg gtggtggtgc ttggactcgt agctggt    47
  • <210> 5

    <211> 27

    <212> DNA

    <213> artificial sequence
  • <220>

    <223> primer
  • <400> 5

    ggaattcata tggtgccgaa ggtgacg    27
  • <210> 6

    <211> 39

    <212> DNA

    <213> artificial sequence
  • <220>

    <223> primer
  • <400> 6

    cgtggccttc cccataagct tctcttctgg cgcgtaggt    39
  • <210> 7

    <211> 24

    <212> DNA

    <213> artificial sequence
  • <220>

    <223> primer
  • <400> 7

    aagcttatgg ggaaggccac gacc    24
  • <210> 8

    <211> 46

    <212> DNA

    <213> artificial sequence
  • <220>

    <223> primer
  • <400> 8

    cgggatccta gtggtggtgg tggtggtgcg cgccgggctt gacagc    46
  • <210> 9

    <211> 27

    <212> DNA

    <213> artificial sequence
  • <220>

    <223> primer
  • <400> 9

    ggaattcata tggtgccgaa ggtgacg    27
  • <210> 10

    <211> 46

    <212> DNA

    <213> artificial sequence
  • <220>

    <223> primer
  • <400> 10

    cgggatccta gtggtggtgg tggtggtgcg cgccgggctt gacagc    46
  • <210> 11

    <211> 30

    <212> DNA

    <213> artificial sequence
  • <220>

    <223> primer
  • <400> 11

    ggaattcata tggggaaggc cacgaccgag    30
  • <210> 12

    <211> 39

    <212> DNA

    <213> artificial sequence
  • <220>

    <223> primer
  • <400> 12

    caccttcggc accataagct tcgcgccggg cttgacagc    39
  • <210> 13

    <211> 24

    <212> DNA

    <213> artificial sequence
  • <220>

    <223> primer
  • <400> 13

    aagcttatgg tgccgaaggt gacg    24
  • <210> 14

    <211> 46

    <212> DNA

    <213> artificial sequence
  • <220>

    <223> primer
  • <400> 14

    cgggatccta gtggtggtgg tggtggtgct cttctggcgc gtaggt    46
  • <210> 15

    <211> 30

    <212> DNA

    <213> artificial sequence
  • <220>

    <223> primer
  • <400> 15

    ggaattcata tggggaaggc cacgaccgag    30
  • <210> 16

    <211> 46

    <212> DNA

    <213> artificial sequence
  • <220>

    <223> primer
  • <400> 16

    cgggatccta gtggtggtgg tggtggtgct cttctggcgc gtaggt    46
  • <210> 17

    <211> 30

    <212> DNA

    <213> artificial sequence
  • <220>

    <223> primer
  • <400> 17

    ggaattcata tggggaaggc cacgaccgag    30
  • <210> 18

    <211> 31

    <212> DNA

    <213> artificial sequence
  • <220>

    <223> primer
  • <400> 18

    gggatttcca tatgctcttc tggcgcgtag g    31


Anspruch[de]
Hybridallergen, das ein Polypeptid ist und mindestens zwei verschiedene allergene Proteine oder Fragmente davon umfasst, wobei jedes Fragment aus mindestens acht aufeinander folgenden Aminosäuren des entsprechenden allergenen Proteins besteht, dadurch gekennzeichnet, dass das allergene Protein, von dem das Hybridpolypeptid stammt, aus immunologisch nicht miteinander verwandten Hauptallergenen aus Timotheegraspollen besteht. Hybridallergen nach Anspruch 1, wobei das Hybridpolypeptid nicht miteinander verwandte Hauptallergene aus Timotheegraspollen umfasst, die ausgewählt sind aus Phl p5/Phl p1, Phl p 2/Phl p 6 und einer Kombination aus allen vier Molekülen. Hybridallergen nach Anspruch 1, wobei das Hybridpolypeptid mindestens ein vollständiges allergenes Protein umfasst. Hybridallergen nach Anspruch 3, wobei das Hybridpolypeptid mindestens zwei vollständige allergene Proteine umfasst. Hybridallergen nach Anspruch 1, wobei das Hybridpolypeptid mindestens ein Fragment eines allergenen Proteins umfasst und wobei das Fragment eine im Vergleich zu dem allergenen Protein, von dem es stammt, im Wesentlichen reduzierte allergene Aktivität aufweist. Hybridallergen nach Anspruch 5, wobei das Hybridpolypeptid Fragmente von mindestens zwei verschiedenen allergenen Proteinen umfasst und wobei jedes dieser Fragmente eine im Vergleich zu den entsprechenden allergenen Proteinen, von denen sie stammen, im Wesentlichen reduzierte allergene Aktivität aufweist. Hybridallergen nach irgendeinem der Ansprüche 1 bis 6, dadurch gekennzeichnet, dass es mindestens drei verschiedene allergene Proteine oder Fragmente davon umfasst. Polynukleotid, das für ein Polypeptid gemäß irgendeinem der Ansprüche 1 bis 7 codiert. Verwendung eines Polynukleotids gemäß Anspruch 8 zur Herstellung eines DNA-Impfstoffs. Zelle, die mit einem Polynukleotid, das ein Polynukleotid gemäß Anspruch 8 umfasst, transfiziert oder transformiert ist. Pharmazeutische Zusammensetzung, die ein Polypeptid gemäß irgendeinem der Ansprüche 1 bis 7, ein Polynukleotid gemäß Anspruch 8 oder eine Zelle gemäß Anspruch 10 enthält. Pharmazeutische Zusammensetzung nach Anspruch 11, die eine Impfstoffzusammensetzung ist. Pharmazeutische Zusammensetzung nach Anspruch 11 oder 12, die ferner einen Hilfsstoff enthält. Verfahren zur Herstellung eines Hybridpolypeptids gemäß irgendeinem der Ansprüche 1 bis 7, das die folgenden Schritte umfasst: a) Bereitstellen eines für das Hybridpolypeptid codierenden Polynukleotids; b) Einschleusen dieses Polynukleotids in eine Wirtszelle; und c) Kultivieren der in Schritt b) erhaltenen Wirtszelle unter Bedingungen, unter denen das Hybridpolypeptid exprimiert wird; und d) Wiedergewinnen des Expressionsprodukts aus der Zelle. Verfahren nach Anspruch 14, wobei das für das Hybridpolypeptid codierende Polynukleotid unter Verwenden von PCR-Technologie hergestellt wird. Verfahren zur Herstellung eines Hybridpolypeptids gemäß irgendeinem der Ansprüche 1 bis 7, dadurch gekennzeichnet, dass das Polypeptid durch chemische Synthese hergestellt wird. Verwendung eines Hybridpolypeptids gemäß irgendeinem der Ansprüche 1 bis 7 oder eines Polynukleotids gemäß Anspruch 8 oder einer Zelle gemäß Anspruch 10 zur Herstellung eines Medikaments zur Behandlung einer allergischen Erkrankung. Verwendung eines Hybridpolypeptids gemäß irgendeinem der Ansprüche 1 bis 7 oder eines Polynukleotids gemäß Anspruch 8 oder einer Zelle gemäß Anspruch 10 zur Herstellung eines Medikaments zur prophylaktischen Impfung oder Toleranzinduktion. Verwendung eines Hybridpolypeptids gemäß irgendeinem der Ansprüche 1 bis 7 zum Nachweis von Antikörpern gegen ein allergenes Protein in einer Probe. Verwendung nach Anspruch 19, wobei der Nachweis durch in vitro-Antikörpertests und Tests unter Verwenden von Zellen durchgeführt wird.
Anspruch[en]
A hybrid allergen which is a polypeptide comprising at least two different allergenic proteins or fragments thereof wherein each fragment consists of at least eight consecutive amino acids of the respective allergenic protein, characterized in that the allergenic protein from which the hybrid polypeptide is derived consists of immunologically unrelated major timothy grass pollen allergens. A hybrid allergen according to claim 1 wherein the hybrid polypeptide comprises unrelated major timothy grass pollen allergens selected from Phl p 5/Phl p 1, Phl p 2/Phl p 6 and a combination of all four molecules. A hybrid allergen according to claim 1 wherein the hybrid polypeptide comprises at least one complete allergenic protein. A hybrid allergen according to claim 3 wherein the hybrid polypeptide comprises at least two complete allergenic proteins. A hybrid allergen according to claim 1 wherein the hybrid polypeptide comprises at least one fragment of an allergenic proteins which fragment has a substantially reduced allergenic activity compared with the allergenic protein from which it is derived. A hybrid allergen according to claim 5 wherein the hybrid polypeptide comprises fragments of at least two different allergenic proteins all of which fragments have a substantially reduced allergenic activity compared with the respective allergenic proteins from which they are derived. A hybrid allergen according to any of claims 1-6 characterized in that it comprises at least three different allergenic proteins or fragments thereof. A polynucleotide encoding a polypeptide according to any of claims 1-7. The use of a polynucleotide according to claim 8 for the preparation of a DNA vaccine. A cell transfected or transformed with a polynucleotide comprising a polynucleotide according to claim 8. A pharmaceutical composition containing a polypeptide according to any of claims 1-7, a polynucleotide according to claim 8 or a cell according to claim 10. A pharmaceutical composition according to claim 11 which is a vaccine composition. A pharmaceutical composition according to claim 11 or 12 further containing an adjuvant. A method for the preparation of a hybrid polypeptide according to any of claims 1-7 comprising the following steps: a) providing a polynucleotide encoding the hybrid polypeptide; b) introducing said polynucleotide into a host cell; and c) culturing the host cell obtained in step b) under conditions such that the hybrid polypeptide is expressed; and d) recovering the expression product from the cell. A method according to claim 14 wherein the polynucleotide encoding the hybrid polypeptide is prepared using PCR technology. A method for the preparation of a hybrid polypeptide according to any of claims 1-7 characterized in that the polypeptide is prepared by chemical synthesis. The use of a hybrid polypeptide according to any of claims 1-7, or of a polynucleotide according to claim 8, or of a cell according to claim 10 for the preparation of a medicament for the treatment of an allergic disorder. The use of a hybrid polypeptide according to any of claims 1-7, or of a polynucleotide according to claim 8 or of a cell according to claim 10 for the preparation of a medicament for prophylactic vaccination or tolerance induction. The use of a hybrid polypeptide according to any of claims 1-7 for the detection of antibodies against an allergenic protein in a sample. The use according to claim 19 wherein the detection is performed by in vitro antibody tests and tests using cells.
Anspruch[fr]
Allergène hybride étant un polypeptide comprenant au moins deux protéines allergéniques différentes ou fragments de celles-ci dans lesquelles chaque fragment est constitué d'au moins huit acides aminés consécutifs de la protéine allergénique respective,

caractérisé en ce que la protéine allergénique à partir de laquelle le polypeptide hybride est dérivé est constituée d'allergènes de pollen de fléole des prés sans lien de parenté majeur sur le plan immunologique.
Allergène hybride selon la revendication 1, dans lequel le polypeptide hybride comprend des allergènes de pollen de fléole des prés sans lien de parenté majeur choisis parmi Phl p5/Phl p1, Phl p2/Phl p6 et une combinaison de ces quatre molécules. Allergène hybride selon la revendication 1, dans lequel le polypeptide hybride comprend au moins une protéine allergénique complète. Allergène hybride selon la revendication 3, dans lequel le polypeptide hybride comprend au moins deux protéines allergéniques complètes. Allergène hybride selon la revendication 1, dans lequel le polypeptide hybride comprend au moins un fragment d'une protéine allergénique, lequel fragment a une activité allergénique substantiellement réduite en comparaison à la protéine allergénique dont il est dérivé. Allergène hybride selon la revendication 5, dans lequel le polypeptide hybride comprend des fragments d'au moins deux protéines allergéniques différentes dont tous les fragments ont une activité allergénique substantiellement réduite en comparaison aux protéines allergéniques respectives dont ils sont dérivés. Allergène hybride selon l'une des revendications 1 à 6

caractérisé en ce qu'il comprend au moins trois protéines allergéniques différentes ou fragments de celles-ci.
Polynucléotide codant un polypeptide selon l'une des revendications 1 à 7. Utilisation d'un polynucléotide selon la revendication 8 pour la préparation d'un vaccin à ADN. Cellule transfectée ou transformée avec un polynucléotide comprenant un polynucléotide selon la revendication 8. Composition pharmaceutique contenant un polypeptide selon l'une des revendications 1 à 7, un polynucléotide selon la revendication 8 ou une cellule selon la revendication 10. Composition pharmaceutique selon la revendication 11 qui est une composition vaccinale. Composition pharmaceutique selon la revendication 11 ou 12 contenant en outre un adjuvant. Procédé pour la préparation d'un polypeptide hybride selon l'une des revendications 1 à 7 comprenant les étapes suivantes consistant à : a) fournir un polynucléotide codant le polypeptide hybride ; b) introduire ledit polynucléotide dans une cellule hôte ; et c) cultiver la cellule hôte obtenue à l'étape b) dans des conditions telles que le polypeptide hybride est exprimé ; et d) recupérer les produit d'expression à partir de la cellule. Procédé selon la revendication 14 dans lequel le polynucléotide codant le polypeptide hybride est préparé en utilisant la technologie PCR. Procédé pour la préparation d'un polypeptide hybride selon l'une des revendications 1 à 7,

caractérisé en ce que le polypeptide est préparé par synthèse chimique.
Utilisation d'un polypeptide hybride selon l'une des revendications 1 à 7, ou d'un polynucléotide selon la revendication 8, ou d'une cellule selon la revendication 10 pour la préparation d'un médicament pour le traitement d'un trouble allergique. Utilisation d'un polypeptide hybride selon l'une des revendications 1 à 7, ou d'un polynucléotide selon la revendication 8, ou d'une cellule selon la revendication 10 pour la préparation d'un médicament pour une vaccination prophylactique ou une induction de tolérance. Utilisation d'un polypeptide hybride selon l'une des revendications 1 à 7 pour la détection d'anticorps contre une protéine allergénique dans un échantillon. Utilisation selon la revendication 19 dans laquelle la détection est effectuée par des tests d'anticorps in vitro et des tests utilisant des cellules.






IPC
A Täglicher Lebensbedarf
B Arbeitsverfahren; Transportieren
C Chemie; Hüttenwesen
D Textilien; Papier
E Bauwesen; Erdbohren; Bergbau
F Maschinenbau; Beleuchtung; Heizung; Waffen; Sprengen
G Physik
H Elektrotechnik

Anmelder
Datum

Patentrecherche

Patent Zeichnungen (PDF)

Copyright © 2008 Patent-De Alle Rechte vorbehalten. eMail: info@patent-de.com